Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 549-551
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae

Patricia M. Roblin and Margaret R. Hammerschlag*

Division of Infectious Diseases, Department of Pediatrics, State University of New York, Health Science Center at Brooklyn, Brooklyn, New York 11203, USA

We compared the activity of gatifloxacin, a new quinolone, ofloxacin and erythromycin against five isolates of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae, including TW183 and clinical isolates from the USA and Japan. Testing was done in cycloheximide-treated HEp-2 cells. Gatifloxacin was slightly less active against C. trachomatis and slightly more active against C. pneumoniae than ofloxacin, with MICs at which 90% of the isolates had no inclusions and minimal chlamydicidal concentrations at which 90% of the isolates had no inclusions after passage of 0.25 mg/L. Gatifloxacin was less active than erythromycin for both species.

* Correspondence address. Department of Pediatrics, Box 49, SUNY Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY 11203-2098, USA. Tel: +1-718-245-4075; Fax: +1-718-245-2118; E-mail: mhammerschlag{at}pol.net


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Ameyama, Y. Shinmura, and M. Takahata
Inhibitory Activities of Quinolones against DNA Gyrase of Chlamydia pneumoniae
Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2327 - 2329.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Trampuz, G. Laifer, M. Wenk, Z. Rajacic, and W. Zimmerli
Pharmacokinetics and Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Granulocyte-Rich Exudate
Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3630 - 3633.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.